Stock info BB Biotech | Filter  Basic-Info

BB Biotech

The company mostly operates in the biotech sector. Over the past 10 years the global biotech companies gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The past year was a profitable year for BB Biotech investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in BB Biotech, the stock lost around 5 percent. Over the past 5 years BB Biotech' stock rose at around 361 percent in value. BB Biotech's revenues between 2011 and 2015 were very volatile and moved between 391,99 million CHFF and 697,95 million CHFF. BB Biotech's net results between 2011 and 2015 were very fluctuating and moved between -65,14 million CHFF and 652,82 million CHFF.

The Swiss company paid out dividends in the past 5 years. On average BB Biotech's dividend yield over the past 5 years was around 7,52 percent annually.

BB Biotech financed with relatively a lot of debt

Last year the balance sheet of the Swiss company was worth 4,14 billion CHFF. Of the total balance sheet 165,51 million CHFF (3,99 percent) was financed by debt. At the end of 2015 the biotech company's stock was traded with a price/earnings-ratio 4. So the stock' value was 4 times the 2015' earnings per share. We could say that based on her price/earnings-ratio and dividend yield the Swiss stock can be seen as a value stock.

The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 3,19 billion CHFF. At the end of 2015 the Swiss company had around 55,85 million stocks listed.

All of BB Biotech's annual reports are stored here. More information about BB Biotech can be found it's website. .